Stephen K Doberstein
CIK 1480111 · SVP & Chief Scientific Officer · last filed 2026-08-27
Stephen K Doberstein is a SVP & Chief Scientific Officer who has filed 43 SEC Form 4 insider transactions across 3 companies since 2010. The most recent filing, for FBRX, was dated Aug 27, 2026. Across all open-market trades the lifetime net is −$30.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $268.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NKTR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94110
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Forte Biosciences, Inc. (FBRX) Delisted | Director | — | $76.99 | — | $0 | 7 | 2026-08-27 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $0 | 4 | 2021-12-29 |
| NKTR | SVP & Chief Scientific Officer | 7,178 | $37.41 | $268.5K | -$30.48M | 32 | 2019-09-09 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-27 | Forte Biosciences, Inc. (FBRX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-06-02 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-22 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-09-20 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-02 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Forte Biosciences, Inc. (FBRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-29 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | −3,333 | -$127.5K | EDGAR |
| 2021-06-07 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Mixed | +3,333 | $0 | EDGAR |
| 2020-06-16 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.